LUTHERVILLE, MD – May 8, 2019 – AgriMetis, LLC is pleased to announce the issuance of a second US patent related to L-glufosinate (Glu-L™). This second patent is part of the Glu-L product family of broad-spectrum herbicides offering an improved alternative to the commercial racemic glufosinate currently offered in the agricultural market.
With issuance of this second patent, US10260078, AgriMetis plans to proceed with initiatives to produce and bring Glu-L™ to market. The new patent outlines novel compositions of matter comprising mixtures of L-glufosinate, D-glufosinate, and PPO. These mixtures are produced during the patent-protected enzymatic process to convert D-glufosinate from racemic glufosinate into L-glufosinate, the active isomer. During the enzymatic process, the first enzyme converts D-glufosinate to PPO. The second converts PPO to L-glufosinate.
The methods outlined in this patent were developed using the approach of intentionally combining synthetic biology, chemistry, and process engineering to solve problems facing the agrichemical industry. (For more information on this patent: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=10,260,078.PN.&OS=PN/10,260,078&RS=PN/10,260,078).
Steven Tuttle, President and CEO of AgriMetis said, “We are pleased to receive this patent and with it comes the culmination of a strong collaboration between our research and development team to produce a safer, more effective approach to weed management for farmers. We protect all aspects of our innovative approach to providing farmers this safer, powerful tool against weeds. AgriMetis plans to continue with the Glu-L patent family focused on continuing highly efficient and lower cost approaches to delivering innovative products to the global agricultural market.”
About AgriMetis: AgriMetis is committed to working with leading agriculture companies and businesses to fill the emerging need for sustainable crop protection products through leading edge and advanced discovery, development and delivery methods. The AgriMetis technology platform is at the interface of biology, biochemistry, and chemistry, employing a multidisciplinary and integrated scientific approach, allowing access to areas of chemical space and production routes that are inaccessible to others. AgriMetis was formed in March 2014 to fund agriculture chemical research and development by applying a biopharmaceutical model. With headquarters near Baltimore, Maryland, AgriMetis continues to grow and develop its technologies and capabilities. For more information, please visit http://www.agrimetis.com.
This press release contains “forward-looking statements” concerning the development and commercialization of AgriMetis products, the potential benefits and attributes of such products, and company expectations regarding prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. AgriMetis undertakes no obligation to update any forward-looking statements for any reason.0